Mitral Valve

The heart's mitral valve is the site of the most surgical valve repairs and valve replacements. After the resounding success of transcatheter aortic valve replacement (TAVR), which now makes up more than 50% of aortic valve replacements, there is wide expectation transcatheter mitral replacements will follow in the next few year. Currently, the most common transcatheter mitral procedure is transcatheter edge-to-edge (TEER) , using the MitraClip or Pascal clip devices. These devices are also being used for transcatheter tricuspid valve repair (TTVR). Other transcatheter mitral repair systems are in trials for minimally invasive annuloplasty and chordae tendineae repair. 

LAMPOON before TMVR improves symptoms without complications, long-term data confirm

LVOT obstruction remains a significant complication of TMVR, making the long-term safety and effectiveness of the LAMPOON technique a hot topic in interventional cardiology.

Thumbnail

Baseline TR linked to lower quality of life after TAVR, M-TEER—are more interventions the answer?

Patients presenting for TAVR or M-TEER with baseline moderate or severe tricuspid regurgitation were associated with lower post-treatment KCCQ scores and a higher mortality rate. Perhaps treating more of these patients with tricuspid valve repair or replacement could make a difference, researchers noted. 

Treating atrial functional mitral regurgitation (AFMR) with surgery may be more beneficial than medical therapy alone, according to new data published in JAMA Network Open.[1]

Atrial functional mitral regurgitation: Surgery improves outcomes more than medical therapy alone

"These findings underscore the importance of understanding AFMR and its treatment options," one cardiologist said.

Treating mitral regurgitation with transcatheter mitral edge-to-edge repair (TEER) using the MitraClip device is associated with a low risk of cerebrovascular accidents (CVAs) such as stroke and transient ischemic attack (TIA), according to new data published in The American Journal of Cardiology.[1]

TEER with Abbott’s MitraClip linked to low stroke risk, new study confirms

Treating severe MR with the popular device does not appear to increase a patient's risk of stroke or transient ischemic attack. When patients present with AFib, however, care teams may want to make certain adjustments to optimize outcomes. 

Cardiovalve heart valve transfemoral TMVR TTVR

Cardiologists first in world to use new heart valve for TMVR, TTVR on same patient

Identical Cardiovalve systems were used to perform the procedures 18 months apart on a high-risk heart patient. 

Echocardiography vs CT for Prediction of Newly Created LVOT Area during TMVR

3D echo comparable to CT for predicting TMVR complications

LVOT obstruction after TMVR remains a significant concern among structural heart cardiologists. Predicting the risk of LVOT obstruction typically requires CT, which comes with certain disadvantages compared to other imaging options.

Edwards Lifesciences Sapien 3 transcatheter heart valve used for Mitral Valve-in-Valve

Transcatheter mitral valve-in-valve replacement benefits intermediate-risk patients

New one-year data suggests transseptal MViV with a Sapien 3 heart valve is a "favorable and safe procedure." Researchers plan to follow patients for a total of 10 years.

Innovalve Bio Medical's Innostay TMVR device. Edwards Lifesciences has agreed to acquire Innovalve after an initial investment in 2017.

Edwards Lifesciences to acquire medical device startup behind new TMVR technology

Edwards, an early investor when the company first launched in 2017, said the acquisition will ensure its TMVR platform reaches as many patients as possible. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

 

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup